Audentes Therapeutics (NASDAQ:BOLD) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Wednesday.

Other equities research analysts have also issued reports about the stock. Bank of America reiterated a “buy” rating and issued a $33.00 price target (up from $23.00) on shares of Audentes Therapeutics in a research note on Friday, September 22nd. ValuEngine lowered shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Evercore ISI assumed coverage on shares of Audentes Therapeutics in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 price target on the stock. Zacks Investment Research lowered shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Finally, Raymond James Financial assumed coverage on shares of Audentes Therapeutics in a research note on Thursday, October 12th. They issued a “market perform” rating on the stock. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $28.29.

Shares of Audentes Therapeutics (NASDAQ:BOLD) traded up $0.24 during mid-day trading on Wednesday, reaching $29.13. 174,543 shares of the company’s stock traded hands, compared to its average volume of 217,480. Audentes Therapeutics has a 12-month low of $13.90 and a 12-month high of $33.43.

Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.88). equities research analysts anticipate that Audentes Therapeutics will post -3.52 earnings per share for the current fiscal year.

In other news, VP Suyash Prasad sold 8,000 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $28.53, for a total transaction of $228,240.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP David Nagler sold 3,750 shares of the business’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $25.00, for a total transaction of $93,750.00. Following the transaction, the senior vice president now owns 3,750 shares in the company, valued at $93,750. The disclosure for this sale can be found here. Insiders have sold a total of 761,500 shares of company stock worth $21,457,100 over the last 90 days. 47.30% of the stock is owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in BOLD. Redmile Group LLC grew its stake in Audentes Therapeutics by 77.8% in the 2nd quarter. Redmile Group LLC now owns 1,459,616 shares of the biotechnology company’s stock valued at $27,922,000 after buying an additional 638,780 shares during the last quarter. Jennison Associates LLC grew its stake in Audentes Therapeutics by 182.4% in the 2nd quarter. Jennison Associates LLC now owns 846,273 shares of the biotechnology company’s stock valued at $16,189,000 after buying an additional 546,617 shares during the last quarter. Perceptive Advisors LLC grew its stake in Audentes Therapeutics by 10.4% in the 3rd quarter. Perceptive Advisors LLC now owns 781,309 shares of the biotechnology company’s stock valued at $21,885,000 after buying an additional 73,809 shares during the last quarter. Vanguard Group Inc. grew its stake in Audentes Therapeutics by 130.3% in the 2nd quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock valued at $12,978,000 after buying an additional 383,837 shares during the last quarter. Finally, Alliancebernstein L.P. grew its stake in Audentes Therapeutics by 31.5% in the 2nd quarter. Alliancebernstein L.P. now owns 640,654 shares of the biotechnology company’s stock valued at $12,256,000 after buying an additional 153,617 shares during the last quarter. Institutional investors own 78.99% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/10/audentes-therapeutics-bold-lowered-to-buy-at-bidaskclub.html.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.